Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 6, 1997, Pages 239-244

  Usui, T ^a   Oiso, Y ^b   Tomita, A ^c   Ogata, E ^d   Uchida, T ^a   Ikeda, K ^a   Watanabe, T ^a   Higuchi, S ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bisphosphonate; Incadronate; Pharmacokinetics; YM175

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; INCADRONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 0030919083     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 32P-EHDP in man. Calcif Tissue Res 22 (Suppl): 428-429
2. Fleisch H 1991 Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944
3. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig, WR 1978 The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 19: 270-275
4. Green JR, Reeve J, Tellez M, Veall N, Wootton R 1987 Skeletal blood flow in metabolic disorders of the skeleton. Bone 8: 293-297
5. Kawamuki K, Abe T, Kudo M, O'uchi N, Motoie H, Usui T, Isomura Y, Takeuchi M, Kawashima H 1990 Effect of YM175 on bone positively correlates with its concentration in bone. J Bone Miner Res 5 (Suppl 2): S245
6. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P 1992 Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84: 788-792
7. Lin JH, Duggan DE, Chen IW, Ellsworth RL 1991 Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19: 926-932
8. Lin JH, Chen IW, DeLuna FA, Hichens M 1992 Renal handling of alendronate in rats: an uncharacterized renal transport system. Drug Metab Dispos 20: 608-613
9. 14C-YM175 to rats. Xenobio Metabol Dispos 9: 835-847
10. Payne RB, Little AJ, Williams KB, Milner JR 1973 Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4: 643-646
11. Pentikäinen PJ, Elomaa I, Nurmi AK, Kärkkäinen K 1989 Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol 27: 222-228
12. Slatopolsky E, Hruska K, Klahr S 1993 Clinical disorders of fluid, electrolyte, and acid-base. In: Schrier RW, Gottschalk CW (eds) Diseases of the Kidney (5th ed, Vol 3). Little, Brown and Company, New York, pp 2599-2644
13. Takeuchi M, Sakamoto S, Yoshida M, Abe T, Isomura Y 1993 Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives. Chem Pharm Bull 41: 688-693
14. Troehler U, Bonjour JP, Fleisch H 1975 Renal secretion of diphosphonates in rats. Kidney Int 8: 6-13
15. Usui T, Watanabe T, Higuchi S 1992 Determination of a new bisphosphonate, YM175, in plasma, urine and bone by high-performance liquid chromatography with electrochemical detection. J Chromatogr 584: 213-220
16. Usui T, Watanabe T, Higuchi S 1995 Pharmacokinetics of YM175, a new bisphosphonate in rats and dogs. Drug Metab Dispos 23: 1214-1219
17. Wingen F, Schmähl D 1987 Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. Arzneimittel-Forschung Drug Res 37: 1037-1042